Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab after ASCT in high-risk DLBCL
NCT03241017Phase 2Withdrawn
- Sponsor
- Insel Gruppe
- Start
- Oct 2017
- Primary completion
- Oct 2021
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
01
Overview
A Phase 2 trial of durvalumab in diffuse large B-cell lymphoma (DLBCL), sponsored by Insel Gruppe. Planned start Oct 2017; status: withdrawn.
02
Drugs
durvalumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03241017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03241017.